News Release

February 12, 2019

Completion of dose administration in all patients in the second cohort in Clinical Trials of RBM-007

We are pleased to announce that the dose administration to all three patients in the second cohort (intermediate dose group) was completed in phase I/IIa trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD). With this, we have completed intravitreal injection of RBM-007 to two-thirds of nine patients planned as entire phase I/IIa trial.

This phase I/IIa trial is an open label, non-controlled, dose-escalating study assessing mainly the safety and tolerability of a single intravitreal injection of RBM-007 in three cohorts (classified according to the injection dose), each of which includes three patients. Up to now, no safety issue has been observed in the trial.

We will start the next dose to the third and final cohort after reviewing the safety in all patients in the second cohort.

See ClinicalTrials.gov for more information:
https://clinicaltrials.gov/ct2/show/NCT03633084

See also our company's website about this trial:
https://www.ribomic.com/eng/pipeline/rbm007.php

Contact: https://www.ribomic.com/eng/contact.php